Naar www.iknl.nl
- Dermatologie > Melanoom
Notificatie richtlijn E-mail richtlijn Naar startpagina oncoline
----------

Laatst gewijzigd: 2016-03-01, Versie: 2.1, Verantwoording: Nederlandse Melanoom Werkgroep, Type: Landelijke richtlijn

Referentielijst

1 - Agarwala S (2009)
Agarwala S.S. (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587–95.
 
2 - Agrawal S (2009)
Agrawal S, Kane JM, Guadagnolo BA et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node –metastatic melanoma. Cancer 2009;115:5836-44.
 
3 - Van AkkooiACJ (2006)
Van AkkooiACJ, De WiltJHW, VerhoefC, SchmitzPIM, Van Geel AN, EggermontAMM et al. Clinical Relevance of Melanoma Micrometastases (<0.1mm) in Sentinel Nodes: are these nodes to be considered negative? Ann Oncol 2006;17:1578-85.
 
4 - van Akkooi ACJ (2008)
van Akkooi ACJ , Nowecki ZI, Voit C, Schaefer-Hesterberg G, Michej W,De Wilt JHW, et al. Sentinel node tumor burden according to the rotterdam criteria is the most important prognostic factor for survival in melanoma patients. A multicenter study in 388 SN positive patients. Ann Surg 2008; 248:949-55.
 
5 - Ali L (2010)
Ali L, Helm T, Cheney R, Conroy J, Sait S, Guitart J, et al. Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms, Int J Clin Exp Pathol. 2010;3:593-9.
 
6 - Ang KK (1990)
Ang KK,Byers RM, Peters LJ, Maor MH, Wendt CD, Morrison WH Byers RM, Peters Lj et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg 1990;116:169-72.
 
7 - Armstrong BK (1988)
Armstrong BK. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun? J Dermatol Surg Oncol 1988; 14: 835-49.
 
8 - Atkins MB (1985)
Atkins MB,Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
 
9 - Autier P (1998)
Autier P, Doré JF. Influence of sunexposures during childhood and during adulthood on melanoma risk. Int J Cancer 1998; 77: 533-7.
 
10 - Badgwell BD (2011)
Badgwell BD, Pierce C, Broadwater JR, Westbrook K, Korourian S, Davis D, Hiatt K, Lee J, Cheung WL, Klimberg VS: Intraoperative sentinel lymph node analysis in melanoma, J Surg Oncol 2011;103:1-5.
 
11 - Bafounta ML (2001)
Bafounta ML, Beauchet A, Aegerter P, et al. Is dermoscopy ((epiluminescende microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001; 137: 1343-50.
 
12 - Balch CM (1980)
Balch CM. Surgical management of regional lymph nodes in cutaneous melanoma. J Am Acad Dermatol 1980;3:511-24.
 
13 - Balch CM (1999)
Balch CM, Ross MI. Sentinel lymphadenectomy for melanoma – is it a substitute for elective lymphadenectomy? Ann Surg Oncol 1999;6:416-7.
 
14 - Balch CM (2001)
Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001 ;19:3622-34.
 
15 - Balch CM (2001)
Balch CM, Soong S-J, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001 ;8:101-8.
 
16 - Balch CM (2001)
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Staging Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol 2001 ;19:3635-48.
 
17 - Balch CM (2009)
Balch CM, Gerschenwald JE, Soong SJ et al. Final version of 2009 AJCC Melanoma staging and classification. J. Clin. Oncol. 2009; 27:6199-6206.
 
18 - Ballo MT (2002)
Ballo MT, Strom EA, Zagars GK, Bedikan AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002:52;4:964-972.
 
19 - Ballo MT (2006)
Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, et al. Combined modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006;64(1):106-113.
 
20 - Barth A (1995)
Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995;75:726-34.
 
21 - Bassères N (1995)
Bassères N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995; 191:199-203.
 
22 - Bastiaannet E (2009)
Bastiaannet E, Wobbes, T., Hoekstra, O.S., et al. Prospective Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in patients with palpable lymph node metastases: Diangnostic accuracy and impact on treatment. Jounal of Clinical Oncology. 2009:27(28): 4774-80.
 
23 - Bataille V (2005)
Bataille V, Boniol M, de Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont AM, Ringborg U, Grivergnee AR, Coebergh JW, Chignol MC, Dore JF, Autier P. A multicenter epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer 2005; 41: 2141-2149.
 
24 - Bauer J (2001)
Bauer J, Metzler G, Rassner G, Garbe C, Blum A. Dermatoscopy turns histopathologists’s attention to the suspicious area in melanocytic lesions. Arch Dermatol. 2001;137: 1338–40.
 
25 - Berrino F (2003)
Berrino F, Capocaccia R, Coleman MP, et al. Survival of cancer patients in Europe: the Eurocare -3 study. In: Ann Oncol 2003;14(suppl 5):v96.
 
26 - Bibault JE (2011)
Bibault JE, Dewas S, Mirabel X, Mortier L, Penel N, Vanseymortier L, et al. E. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011;6:12-21.
 
27 - Binder M (1997)
Binder M, Puespoeck-Schwarz M, Steiner A, et al. Epiluminescence microscopy of small pigmented lesions: Short-term formal training improves the diagnostic performance of dermatologists. J Am Acad Dermatol 1997;36:197-202.
 
28 - Bishop DT (2009)
Bishop DT, et al., Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet. 2009 Aug; 41(8):920-5.
 
29 - Bishop DT (2002)
Bishop DT, Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl. Cancer Inst. 2002; 94(12):894-903.
 
30 - Blaheta HJ (2001)
Blaheta HJ, Schittek B, Breuninger H, Garbe C: Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma, Recent Results Cancer Res 2001, 158:137-146.
 
31 - Blaheta HJ (1999)
Blaheta HJ, Schittek B, Breuninger H, Sotlar K, Ellwanger U, Thelen MH, et al. Detection of melanoma micrometastasis in sentinal nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin, Am J Surg Pathol 1999, 23:822-8.
 
32 - Boon A (2008)
Boon A. J. Response to: 'Malignant melanoma re-excision specimens: is there a need for histopathological analysis?' McGoldrick et al., J Plast Reconstr Aesthet Surg 2008; 61:1246.
 
33 - Brady MS (2006)
Brady MS, Akhurst T, Spankneber K, et al.Utility of preoperative [18F]Fluorodeoxyglucose Positron Emission Tomography scanning in high-riks melanoma patients. Annals of Surgical Oncology. 2006;13 (4): 525-532.
 
34 - Braun RP (2009)
Braun RP, Rabinovitz H, Tzu JE, Marghoob AA. Dermoscopy Research-an update. Semin Cutan Med Surg 2009; 28: 165-71.
 
35 - Busam KJ (2008)
Busam KJ, Pulitzer M: Sentinel lymph node biopsy for patients with diagnostically controversial Spitzoid melanocytic tumors?, Adv Anat Pathol 2008, 15:253-62.
 
36 - Cameron DA (2001)
Cameron DA, Cornbleet MC, MacKie RM, et al. Adjuvant interferon alpha in high-risk melanoma: The Scottish study. Br J Cancer 2001;84:1146-9.
 
37 - Cascinelli N (2000)
Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol 2000;7:469-74.
 
38 - Cascinelli N (2001)
Cascinelli N, Belli F, Mackie RM, et al. Effect of long-term adjuvant therapy with interferon-alpha2a in patients with regional node metastases from cutaneous melanoma: A randomized trial. Lancet 2001;358:866-9.
 
39 - Cerroni L (2008)
Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008, Am J Surg Pathol 34:314-26.
 
40 - Chang DT (2006)
Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006;66:1051-5.
 
41 - Chapman PB (1998)
Chapman PB, Parkinson DR, Kirkwood JM. Biologic therapy. In: Cutaneous melanoma. 3rd ed. Balch CM, Houghton AN, Sober AJ, Soong SJ (eds). QMP Inc, 1998:419-36.
 
42 - Chapman PB (1999)
Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
 
43 - Chapman PB (2011)
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5.
 
44 - Ch'ng S (2012)
Ch'ng S, Pinna A, Ioannou K, Juszczyk K, Shannon K, Clifford A, Uren R, Clark JR. Assessment of second tier lymph nodes in melanoma and implications for extent of elective neck dissection in metastatic cutaneous malignancy of the parotid. Head Neck. 2012 Jan 31. doi: 10.1002/hed.22948. [Epub ahead of print].
 
45 - Cho E (2005)
Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin oncol 2005;23:2669-75.
 
46 - Clark GS (2008)
Clark GS, Pappas-Politis EC, Cherpelis BS, et al. Surgical management of melanoma in situ on chronically sun-damaged skin. Cancer Control 2008;15:216-24.
 
47 - Clary BM (2001)
Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250-8.
 
48 - Cochran AJ (1988)
Cochran AJ, Wen DR, Morton DL: Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study, Am J Surg Pathol 1988, 12:612-8.
 
49 - Cochran AJ (2000)
Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236-41.
 
50 - Cochrane DB (2000)
Cochrane DB. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000;CD001215.
 
51 - Cohn-Cedermark G (2000)
Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0-8.-2.0 mm. Cancer 2000;89:1495-501.
 
52 - Collas H (1999)
Collas H, Delbarre M, Preville PA de, Courville P, Neveu C, Dompmartin A, et al. Evaluation of the diagnosis of pigmented tumors of the skin and factors leading to a decision to excise. Dermatologists of the Postgraduate Association of Haute-Normandie. Ann Dermatol Venereol 1999;126:494-500.
 
53 - Cook MG (2008)
Cook MG, Di Palma S: Pathology of sentinel lymph nodes for melanoma, J Clin Pathol 2008, 61:897-902.
 
54 - Cook MG (2003)
Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, et al.: The development of optimal pathological assessment of sentinel lymph nodes for melanoma, J Pathol 2003, 200:314-319.
 
55 - Cordova A et al. (2006)
Cordova A et al., 18 Fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) imaging versus sentinel lymph node biopsy (SLNB) in the staging of cutaneous melanoma in AJCC stage I and II. Chirurgia. 2006 (of Publication: Jun 2006): p. 19 (3) (pp 189-191).
 
56 - Creagan ET (1995)
Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized surgical adjuvant clinical trial of recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-83.
 
57 - Creagan ET (1999)
Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999;17:1884-90.
 
58 - Creager AJ (2002)
Creager AJ, Shiver SA, Shen P, Geisinger KR, Levine EA: Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology, Cancer 2002, 94:3016-22.
 
59 - Curtin JA (2005)
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al.Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17;353(20):2135-47.
 
60 - Cust AE (2011)
Cust AE, Armstrong BK, Goumas C, Jenkins MA, Schmid H, Hopper JL, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer. 2011; 128: 2425-35.
 
61 - Da Forno PD (2009)
Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L, Saldanha G: BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance, Br J Dermatol 2009, 161:364-72.
 
62 - Daryanani D (2003)
Daryanani D, Plukker JTh, Hullu de JA, Kuiper H, Nap RE, Hoekstra HJ. Pregnancy and early stage melanoma. Cancer 2003;97:2248-53.
 
63 - Day CL (1981)
Day CL, Harrist TJ, Gorstein F, Sober AJ, Lew RA, Friedman RJ, et al. Malignant melanoma. Prognostic significance of ‘microscopic satellites’ in the reticular dermis and subcutaneous fat. Ann Surg 1981;194:108-12.
 
64 - Demenais F (2010)
Demenais F, et al., Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010; 102(20):1568-83.
 
65 - Dessureault S (2001)
Dessureault S, Soong SJ, Ross MI, et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001;8:766-70.
 
66 - Dewar DJ (2004)
Dewar DJ, Newell B, Green MA, Topping AP, Powell BW, Cook MG: The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement, J Clin Oncol 2004, 22:3345-3349.
 
67 - van Dijk MC (2005)
van Dijk MC, Bernsen MR, Ruiter DJ: Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma, Am J Surg Pathol 2005, 29:1145-1151.
 
68 - Eggermont AMM (2003)
Eggermont AMM, Suciu S, Ruka A, et al. Analysis of the EORTC Melanoma Group 18952 randomized trial on 2 intermediate dose schedules of IFN-alpha2b compared with observation in 1388 patients with high risk melanoma stages IIB-III. Eur J Cancer 2003;39:S319.
 
69 - Eggermont AMM (2003)
Eggermont AMM, Geel AN van, Wilt JHW de, Hagen TLM ten. The role of isolated limb perfusion for melanoma confined to the extremities. Surg Clin North Am 2003;83:371-84.
 
70 - Eggermont AM (2004)
Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004 Aug;40(12):1825-36. Review
 
71 - Eggermont AM (2005)
Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al.EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.Lancet. 2005 Oct 1;366(9492):1189-96.
 
72 - Eggermont AM (2008)
Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-26.
 
73 - Elder DE (2004)
Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology 2004; 36(5): 428-34.
 
74 - Engen van (2010)
Engen van, Grunsven van AC, Dijk van MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WA. HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features, Am J Surg Pathol 2010;34:1436-41.
 
75 - El Ghissassi F (2009)
El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V,et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--part D: radiation. Lancet Oncol. 2009; 10: 751-2.
 
76 - Essner R (1999)
Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999;6:442-9.
 
77 - Estourgie SH (2003)
Estourgie SH, Nieweg OE, Valdés Olmos RA, Kroon BBR. A review and evaluation of sentinelnodebiopsies in 250 patients with cutaneous melanoma with a median follow up of six years. Ann Surg Oncol 2003;10:681-8.
 
78 - Eton O (2002)
Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
 
79 - van Everdingen JJE (2005)
van Everdingen JJE, van der Rhee HJ, Koning CCE et al. Richtlijn 'Melanoom' (3e herziening) Ned Tijdschr Geneeskd. 2005;149:1839-43.
 
80 - Facey K. (2007)
Facey K., Bradbury I, Laking G, Payne E. Overview of het clinical effecttiveness of positron emissoin tomography imaging in selected cancers. Health Technology Assessment. 2007;11(44).
 
81 - Falkson CI (1998)
Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-51.
 
82 - Fargnoli MC (2010)
Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S. MC1R variant increase melanoma risk in families with CDKN2A mutaions: a meta-analysis. Eur J Cancer. 2010; 46: 1413-20.
 
83 - Fears TR (2006)
Fears TR, DuPont Guerry IV, Pfeifer RM, Sagebiel RW, Elder DE, Halpern A et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006; 24:3590-6.
 
84 - Ferrara G (2009)
Ferrara G, Argenyi Z, Argenziano G, Cerio R, Cerroni L, et al. The Influence of Clinical Information in the Histopathologic Diagnosis of Melanocytic. PLoS One. 2009;4(4):e5375. Epub 2009 Apr 30.
 
85 - Ferrara G (2004)
Ferrara G, Argenziano G, Cerroni L, Cusano F, Di Blasi A, et al. A pilot study on combined dermoscopic-pathological approach to the telediagnosis of melanocytic skin neoplasms. J Telemed Telecare. 2004;10: 34–8.
 
86 - Ferrara G (2005)
Ferrara G, Argenziano G, Soyer HP, Chimenti S, Di Blasi A, et al. The spectrum of Spitz nevi: a clinicopathologic study of 83 cases. Arch Dermatol. 2005;141: 1381–7.
 
87 - Ferrara G (2008)
Ferrara G, Zalaudek, Argenziano G (2008) Lentiginous melanoma: a distinctive clinicopathological entity. Histopathology. 2008; 52: 523–5.
 
88 - Finkelstein SE (2004)
Finkelstein SE, Carrasquillo JA, Hoffman JM et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11(8):731-8.
 
89 - Flaherty KT (2010)
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. NEJM 2010; 363:809-19.
 
90 - Fogarty GB (2006)
Fogarty GB, TartagliaC. The Utility of Magnetic Resonance Imaging in the Detection of Brain Metastases in the Staging of Cutaneous Melanoma. Clinical Oncology, 2006(of Publication: May 2006): p. 18 (4) (pp 360-362), 2006.
 
91 - Fortes et al. (2010)
Fortes et al., Identifying individuals at high risk of melanoma: a simple tool. Eur J Cancer Prev 2010; 19:393–400.
 
92 - Fraker DL (2002)
Fraker DL, Alexander MR, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF)plus interferon gamma (IFN). Ann Surg Oncol 2002;9:s8.
 
93 - Gandini et al (2005)
Gandini et al . Meta-analysis for risk factors for cutaneous melanoma: I Common and atypical nevi. Eur J Cancer 2005; 41:28-44.
 
94 - Gandini S (2005)
Gandini S, Sera F, Cattaruzza MS Pasquini P, Picconi O, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure. Eur J Cancer 2005; 41:45-60.
 
95 - Gandini et al (2005)
Gandini et al. Meta-analysis for risk factors for cutaneous melanoma: III: Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-2059.
 
96 - Garbe C (2008)
Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.Ann Oncol. 2008 Jun;19(6):1195-201. Epub 2008 Feb 14.
 
97 - Gershenwald JE (1998)
Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-60.
 
98 - Gershenwald JE (2008)
Gershenwald JE, Andtbacka RH, Prieto VG, Johnson MM, Diwan AH, Lee JE, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma, J Clin Oncol 2008, 26:4296-303.
 
99 - Gillgren P (2011)
Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Månsson-Brahme E, Ingvar C, Ringborg U. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011 Nov 5;378(9803):1635-42. Epub 2011 Oct 23. Erratum in: Lancet. 2011 Nov 5;378(9803):1626.
 
100 - Goldstein AM (2006)
Goldstein AM, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66(20):9818-28.
 
101 - Govindarajan A (2007)
Govindarajan A, Ghazarian DM, McCready DR, Leong WL: Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse, Ann Surg Oncol 2007, 14:906-12.
 
102 - Grob JJ (1998)
Grob JJ, Dreno B, Chastang C, et al. Randomised trial of interferon-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998;351:1905-10.
 
103 - Guitera P (2011)
Guitera P, Menzies SW. State of the art of diagnostic technology for early-stage melanoma. Expert Rev Anticancer Ther 2011; 11(5): 715-23 Expert Reviews.
 
104 - Gulec SA (2003)
Gulec SA, Faries MB, Lee CC, Kirgan D et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28(12):961-5.
 
105 - Gutzmer R (2002)
Gutzmer R, Kaspari M, Brodersen JP, Mommert S, Volker B, Kapp A, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies, Histopathology 2002, 41:510-8.
 
106 - Gutzmer R (2005)
Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. British Journal of Dermatology 2005;153(6):1137-41.
 
107 - De Gruijl F (2010)
De Gruijl F. Signaleringscommissie Kanker van de Nederlandse Kankerbestrijding/Koningin Wilhelmina Fonds (KWF Kankerbestrijding). De relatie tussen kanker, zonnestraling en vitamine D. 2010, ISBN 978-90-71229-21-3.
 
108 - Haigh PI (2003)
Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003;46:419-26.
 
109 - Hancock BW (2004)
Hancock BW, Wheatley K, Harrison G, et al. Adjuvant interferon in high-risk melanoma: The Aim High Study – United Kingdom Coordinating Committee on Cancer Research randomised study adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53-61.
 
110 - Hansson J (2007)
Hansson J, Bergenmar M, Hofer PA, Lundell G, Mansson-Brahme E, Ringborg U et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. J. Clin. Oncol. 2007;25: 2819-24.
 
111 - Harinck F et al (2010)
Harinck F et al. Is early diagnosis of pancreatic cancer fiction? Surveillance of individuals at high risk for pancreatic cancer. Dig.Dis. 2010; 28: 670-8.
 
112 - Harlow SP (2001)
Harlow SP, Krag DN, Ashikaga T, et al. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res 2001;11:45-55.
 
113 - Harvell JD (2004)
Harvell JD, Kohler S, Zhu S, Hernandez-Boussard T, Pollack JR, van de Rijn M: High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas, Diagn Mol Pathol 2004, 13:22-25.
 
114 - Heaton KM (1998)
Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (> 4mm) primary melanoma. Ann Surg Oncol 1998;5:322-8.
 
115 - Henderson MA (2009)
Henderson MA, Burmeister b, Thompson JF, Di lulio J, Fisher R, Hong A, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TrOG 02.01). J Clin Oncol, 2009 (jun 20), vol 27 (18S).
 
116 - Héry C (2010)
Héry C, Tryggvadottir L, Sigurdsson T, Olafsdottir E, Sigurgeirsson B, Jonasson JG, et al. A melanoma epidemic in Iceland Am. J, Epidemiol 2010;172:762-767.
 
117 - Hille ET (1994)
Hille ET, van Duijn E, Gruis NA, Rosendaal FR, Bergman W, Vandenbroucke JP. Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole – melanoma syndrome from 1830-1994. J Invest Dermatol 1998; 110:788-92.
 
118 - Hocevar M et al (2004)
Hocevar M et al. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Research. 2004(of Publication: Dec 2004): p. 14 (6) (pp 533-6), 2004
 
119 - Hochberg M (2002)
Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD: Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma, Br J Dermatol 2002, 146:244-249.
 
120 - Hodi FS (2010)
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363:711-23.
 
121 - Hollestein LM (2011)
Hollestein LM, van den Akker SA, Nijsten T, Karim-Kos HE, Coebergh JW, de Vries E. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol. 2011 May 4. [Epub ahead of print].
 
122 - Holly EA (1994)
Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev 1994;3:661-8.
 
123 - Holly EA (1995)
Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III Reproductive factors and oral contraceptive use. Am J Epidemiol 1995;141:943-50
 
124 - Hsueh EC (2002)
Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O’Day SJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002;20:4549-54
 
125 - Huncharek M (2001)
Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.Melanoma Res 2001;11:75-81
 
126 - Hwu WJ (2003)
Hwu WJ, Balch CM, Houghton AN. Diagnosis of stage IV disease. Cutaneous melanoma. Balch CM, Houghton AN, Sober AJ, Soong SJ (eds). 2003:523-46.
 
127 - Iagaru A (2006)
Iagaru A, Quon A, Johnson D et al. 2-Deoxy -2-[18F]Fluorodeoxyglucose Positron Emission Tomography / Computd Tomography in the management of melanoma. Molecular Imaging and Biology. 2006;9: 50-7.
 
128 - International Ag (2006)
International Ag. Internationale Agency for Research on Cancer Working Group on artificial ultraviolat light and skin cancer. The association of use of sunbeds with cutaneouas melanoma and other skin cancers: a systematic review. IARC Rapport, Lyon, 2006.
 
129 - Izikson L (2002)
Izikson L, Sober AJ, Mihm MC Jr, Zembowicz A. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases. Arch Dermatol 2002;138:1562-66.
 
130 - Johnson R (1998)
Johnson R, Sviland L. Is extensive histological examination of wide excision specimens necessary following a diagnosis of emlanoma? Histopathology 1998; 32: 379-80.
 
131 - Kammula US (2004)
Kammula US, Ghossein R, Bhattacharya S, Coit DG: Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients, J Clin Oncol 2004, 22:3989-3996.
 
132 - Kapteijn BAE (1996)
Kapteijn BAE, Nieweg OE, Valdés Olmos RA, et al. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with cutaneous melanoma. J Nucl Med 1996;37:972-5.
 
133 - Karakousis CP (1994)
Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 1994;115:295-302.
 
134 - Karim-Kos HE (2008)
Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s.Eur J Cancer. 2008 Jul;44(10):1345-89. Epub 2008 Feb 14.
 
135 - Kefford et al (2010)
Kefford et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15s, 2010 (suppl; 2010 ASCO Annual Meeting abstr 8503)
 
136 - Keilholz U (1997)
Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-88.
 
137 - Kell M (2007)
Kell M.R et al. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. European Journal of Surgical Oncology, 2007(of Publication: Sep 2007): p. 33 (7) (pp 911-913), 2007.
 
138 - Kelly JW (1984)
Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984;200:759-63
 
139 - Khayat D (2003)
Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1 mm thick). Long-term results of a large European multicentric phase III study. Cancer 2003;97:1941-6.
 
140 - Kirkwood JM (2000)
Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18;2444-59.
 
141 - Kirkwood JM (1996)
Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon-_2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
 
142 - Kirkwood JM (2001)
Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
 
143 - Kirkwood JM (2001)
Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter ECOG phase II trial E 2696. J Clin Oncol 2001;19(5):430-6.
 
144 - Kittler H (2002)
Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accuracy of dermoscopy. Lancet oncol 2002; 3: 159-65.
 
145 - Klaase JM (1994)
Klaase JM, Kroon BB, Geel AN van, Eggermont AM, Franklin HR, Hart AA. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115:39-45.
 
146 - Kleeberg UR (2004)
Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, et al. Eortc Melanoma Group in cooperation with the GERMAN CANCER SOCIETY (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40 (3): 390-402, 2004.
 
147 - Klode J et al (2010)
Klode J et al. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: A retrospective analysis of 61 patients with malignant melanoma in American joint committee on cancer stages i and II. Dermatologic Surgery, 2010(of Publication: April 2010): p. 36 (4) (pp 439-45), 2010.
 
148 - Koopal SA (2000)
Koopal SA, Tiebosch AT, Albertus Piers D, Plukker JT, Schraffordt et al: Frozen section analysis of sentinel lymph nodes in melanoma patients, Cancer 2000, 89:1720-1725.
 
149 - Koskivuo I (2007)
Koskivuo I, Talve L, Vihinen P, Maki M, Vahlberg T, Suominen E. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Annals of Surgical Oncology 2007;14(12):3566-74
 
150 - Kovalyshyn I (2009)
Kovalyshyn I, Braun R, Marghoob A. Congenital melanocytic maevi. Australas J Dermatol 2009; 50: 231-40; quiz 241-2.
 
151 - Krengel S (2006)
Krengel S, Hauschild A, Schäfer T. Melanoma risk in congenital melanocytic naevi: a systematic review. BR J Dermatol 2006; 155: 1-8.
 
152 - Krug B et al (2008)
Krug B et al. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology, 2008(of Publication: Dec 2008): p. 249 (3) (pp 836-844), 2008.
 
153 - Lazovich D (2010)
Lazovich D, Isaksson Vogel R, Berwick M. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkerss Prev. 2010; 19: 1557-1568.
 
154 - Leachman SA (2009)
Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009; 61: 677-84.
 
155 - Lee JB (2010)
Lee JB, Hirokawa D. Dermatoscopy: Facts and controversias. Clin Dermatol 2010; 28: 303-310.
 
156 - Lee RJ (2000)
Lee RJ, Gibbs JF, Proulx GM, et al. Nodal basin recurrence after lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000;46:467-74
 
157 - Leiter U (2010)
Leiter U, Buettner PG, Bohnenberger K, Eigentler T, Meier F, Moehrle M, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Annals of Surgical Oncology 2010;17(1):129-37
 
158 - Lens MB (2002)
Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy.Br J Surg 2002;89:1223-7.
 
159 - Lens MB (2002)
Lens MB, Dawes M, Goodacre T, Newton Bishop JA. Excision margins in the treatment of primary cutaneous melanoma. A systematic review of randomized controlled trials comparing narrow versus wide excision. Arch Surg 2002;137:1101-5.
 
160 - Lens MB (2002)
Lens MB, Dawes M. Interferon-alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-25.
 
161 - MacKie (2002)
MacKie, Fleming C, McMahon AD, et al. The use of the dermatocope to identify early melanoma using the three-colour test. Br J Dermatol 2002; 146: 481-4.
 
162 - Mackie RM (1991)
Mackie RM, Bufalino R, Morabito A, et al. Lack of effect of pregnancy on outcome of melanoma. Lancet 1991;I:653-5.
 
163 - Mackie RM (1996)
Mackie RM, Cascinelli N, Ross MI, Santinami M, McCarthy WH. Clinical management of melanoma. WHO Melanoma Programme. WHO Melanoma Programme Publications, 1996.
 
164 - Mahmood MN (2002)
Mahmood MN, Lee MW, Linden MD, Nathanson SD, Hornyak TJ, Zarbo RJ: Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells, Mod Pathol 2002, 15:1288-93.
 
165 - Mangas C (2006)
Mangas C, Hilari JM, Paradelo C, Rex J, Fernandez-Figueras MT, Fraile M, Alastrue A, et al.: Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients, Ann Surg Oncol 2006, 13:910-8.
 
166 - Marks R (1994)
Marks R, Whiteman D. Sunburn and melanoma: how strong is the evidence? BMJ 1994; 308:75–6.
 
167 - Marsden JR (2010)
Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al: Revised UK guidelines for the management of cutaneous melanoma 2010, J Plast Reconstr Aesthet Surg 2010, 63:1401-19.
 
168 - Martin HM et al (1998)
Martin HM et al. Malignant melanoma re-excision specimens – how many blocks? Histopathology 1998; 32: 362-7.
 
169 - Masri GD (1990)
Masri GD, Clark WH Jr., Guerry D, Halpern A, Thompson CJ, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J. Am. Acad. Dermatol. 1990; 22:1042-8.
 
170 - Mayer J (1997)
Mayer J. Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Med J Aust 1997; 167: 206-10
 
171 - McGoldrick et al (2008)
McGoldrick et al. Malignant melanoma re-excision specimens: is there a need for histopathological analysis? J Plast Reconstr Aesthet Surg 2008; 61:983-4.
 
172 - Messina JL (1999)
Messina JL, Glass LF, Cruse CW, Berman C, Ku NK, Reintgen DS: Pathologic examination of the sentinel lymph node in malignant melanoma, Am J Surg Pathol 1999, 23:686-90.
 
173 - Meyskens FL (1994)
Meyskens FL, Liu PY, Tuthill RJ, et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1994;12:2060-5.
 
174 - Middleton M (2000)
Middleton M, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66. Erratum in: J Clin Oncol 2000;18:2351.
 
175 - Mocellin S (2010)
Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501.
 
176 - Moehrle M (2006)
Moehrle M, Dietz K, Garbe C, Breuninger H. Conventional histology vs three-dimensional histology in lentigo maligna melanoma. Br J Dermatol 2006;154:453-9
 
177 - Morton DL (1992)
Morton DL, Wen D, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
 
178 - Morton DL (1999)
Morton DL, Bostick PJ. Will the true sentinel node please stand? Ann Surg Oncol 1999;6:12-4.
 
179 - Morton DL (1999)
Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63.
 
180 - Morton DL (2005)
Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Annals of Surgery 2005;242(3):302-11.
 
181 - Morton DL (2006)
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med 2006;355(13):1307-17.
 
182 - Newton Bishop JA (2002)
Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, et al. UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 2002;55:46-54.
 
183 - Ng AK (2001)
Ng AK, Jones WO, Shaw JH. Analysis of local recurrence and optimizing excision margins for cutaneous melanoma. Br J Surg 2001;88:137-42.
 
184 - Nieweg OE (1998)
Nieweg OE, Jansen L, Kroon BBR. Technique of lymphatic mapping and sentinel node biopsy for melanoma. Eur J Surg Oncol 1998;24:520-4.
 
185 - Nieweg OE (2001)
Nieweg OE, Jansen L, Tanis PJ, Vries JDH de, Kroon BBR. Verbeterde prognose van melanoma cutis door schildwacht- klierprocedure is nog niet aangetoond. Ned Tijdschr Dermatol Venereol 2001;11:246-8.
 
186 - Nieweg OE (2001)
Nieweg OE. A response to Lee M. Ellis’s editorial: A perspective on sentinel lymph node biopsy in colorectal cancer: the race between surgical technology and molecular oncology. Ann Surg Oncol 2001;8:271.
 
187 - Nieweg OE (2001)
Nieweg OE, Tanis PJ, Rutgers EJT. Summary of the second international sentinel node conference. Eur J Nucl Med 2001;28:646-9
 
188 - Nieweg OE (2001)
Nieweg OE, Tanis PJ, Kroon BBR. The definition of a sentinel node. Ann Surg Oncol 2001;9:538-41.
 
189 - NIH (1992)
NIH, Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.
 
190 - Veronesi U (1991)
Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438-41.
 
191 - Orfanos CE (1994)
Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C. Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnosik, Behandlung und Nachsorge des malignen Melanoms der Haut. Hautarzt 1994;45:285-91.
 
192 - Otley CC (2000)
Otley CC, Zitelli JA. Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigational modalities. Dermatol Surg 2000;26:177-80.
 
193 - Overgaard J (1985)
Overgaard J, von der Maasse H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 1985;11:1837-1839.
 
194 - Overgaard J (1995)
Overgaard J, Gonzales Gonzales D, Hulshof MC, Arcangeli G, Dahl O, Mella O, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet.1995;345:540-3.
 
195 - Overgaard J (2009)
Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hyperthermia 2009; 25(5): 323-34.
 
196 - Palmieri G (2001)
Palmieri G, Ascierto PA, Cossu A, Mozzillo N, Motti ML, Satriano SM, et al.: Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay, J Clin Oncol 2001, 19:1437-43.
 
197 - Patel NG et al (2010)
Patel NG et al. Malignant melanoma re-excision specimens: the need for analysis.J. Plast Reconstr Aesth Surg 2010; 63: e653-4.
 
198 - Patel et al (2009)
Patel et al. Ann Oncol, 2009 suppl
 
199 - Pehamberger H (1998)
Pehamberger H, Soyer P, Steiner A, et al. Adjuvant interferon _-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425-9.
 
200 - Pfannenberg C (2007)
Pfannenberg C, Aschoff P, Schanz S et al. Prospective comparison of [18F]Fluorode-oxyglucose Positron Emission Tomography. Computed Tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. European Journal of Cancer 2007;43: 557-64.
 
201 - Pijpers R (1997)
Pijpers R, Borgstein PJ, Meijer S, Hoekstra OS, Hattum LH van, Teule GJ. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 1997 Oct;21(8):788-92; discussion 793
 
202 - Pirard D (2004)
Pirard D, Heenen M, Melot C, Vereecken P.Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.Dermatology. 2004;208(1):43-8.
 
203 - Van der Ploeg AP (2011)
Van der Ploeg AP, Van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria, J Clin Oncol 2011, 29:2206-14.
 
204 - Van der Ploeg IM (2009)
Van der Ploeg IM, Kroon BB, Antonini N, Valdes Olmos RA, Nieweg OE: Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node, Ann Surg 2009, 250:301-4.
 
205 - Van der Ploeg AP (2011)
Van der Ploeg AP, van Akkooi AC, Schmitz PI, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol. 2011 Nov;18(12):3300-8. Epub 2011 May 3.
 
206 - Van Poll D (2005)
Van Poll D, Thompson JF, Colman MH, McKinnon JG, Saw RPM, Stretch JR, et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Annals of Surgical Oncology 2005;12(8):597-608.
 
207 - Price HN (2010)
Price HN, Schaffer JV. Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies. Clin Dermatol 2010: 28: 293-302.
 
208 - Prieto VG (2010)
Prieto VG. Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion, Arch Pathol Lab Med 2010;134:1764-9.
 
209 - Psaty EL (2010)
Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining the patient at risk for melanoma. Intern J Dermatol 2010;49:362-76.
 
210 - Punt CJA (2001)
Punt CJA, Eggermont AMM. Adjuvant interferon-alpha for melanoma revisited: News from old and new studies. Ann Oncol 2001;12:1663-6
 
211 - Que´reux et al (2010)
Que´reux et al. Creation and test of a questionnaire for self-assessment of melanoma risk factors. Eur J Cancer Prev 2010; 19:48–54.
 
212 - Raimondi S (2008)
Raimondi S, Sera F, Gandini S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008; 122(12):2753–60.
 
213 - Rajpar S (2006)
Rajpar S, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006;155:653-6.
 
214 - IGZ (2009)
IGZ, rapport. Rapport van de Inspectie voor de Gezondheidszorg, Ministerie voor Volksgezondheid, Welzijn en Sport. Zorgketen voor kankerpatiënten moet verbeteren. Onderzoek naar de kwaliteit van de oncologische zorgketen voor patiënten die worden behandeld met radiotherapie. Den Haag, maart 2009
 
215 - Reinhardt MJ (2006)
Reinhardt MJ, Joe AY, Jaeger U et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consectutive patients. Journal of Clinical Onology. 2006; 24 (7): 1178-86.
 
216 - Reintgen D (1994)
Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
 
217 - van der Rhee JI (2011)
van der Rhee JI, de Snoo FA, Vasen HF, et al. Effectiveness and causes for failure of surveillance of CDKN2A-mutated melanoma families. J Am Acad Dermatol. 2011 Aug;65(2):289-96. Epub 2011 May 12.
 
218 - van der Rhee JI (2011)
van der Rhee JI, Krijnen P, Gruis NA, de Snoo FA, Vasen HF, Putter H, Kukutsch NA, Bergman W. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol. 2011 Aug;65(2):281-8. Epub 2011 May 12.
 
219 - Riber-Hansen R (2009)
Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, Steiniche T: The nodal location of metastases in melanoma sentinel lymph nodes, Am J Surg Pathol 2009, 33:1522-8.
 
220 - Rice ZP (2010)
Rice ZP, Weiss FJ, DeLong LK, Curiel-Lewandrowski, Chen SC. Utilization and rationale for the implementation of Total body (digital) photography as an adjunct screening mesure for melanoma. Melanoma Research 2010; 20: 417-21.
 
221 - Van Rijk MC et al. (2006)
Van Rijk MC et al., Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol, 2006 Nov13;(11):1511-6.
 
222 - Robbins KT (2002)
Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, Som P, Wolf GT. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. 2002 ;128:751-8.
 
223 - Robert C (2011)
Robert C, Thomas L, Bondarenko, O'Day S, Weber J, Garbe K, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Eng J Med Jun 5 [Epub ahead of print]
 
224 - Römer W (2006)
Römer W, Nörmayr A, Fiedler E et al . Retrospective interactive rigid fusion of 18F-FDG PET and CT. Nuklearmedzin. 2006;45: 88-95.
 
225 - Roozendaal GK (2001)
Roozendaal GK, Vries JDH de, Poll D van, et al. Sentinel nodes outside lymph node basins in melanoma patients. Br J Surg 2001;88:305-8.
 
226 - Roozendaal GK (2000)
Roozendaal GK, de Vries JDH de, Poll D van, Jansen L, Schraffordt Koops H, et al. Sentinel nodes outside lymph node basins in melanoma patients. Br J Surg 2000;88:305-8.
 
227 - Rosenberg SA (1999)
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75.
 
228 - Salerni G (2011)
Salerni G, Carrera C, Lovatto L, Puig-Butille JA, Badenas C, Plana E, et al. Benefits of total body photography and digital dermatoscopy in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol. 2012 Jul;67(1):e17-27. Epub 2011 Jun 16..
 
229 - Sanki A et al. (2009)
Sanki A et al., Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol 2009(Nov) 27(33):5614-9.
 
230 - Sause WT (1991)
Sause WT, Cooper JS, Rush S et al. Fraction size in external beam radiation beam therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991;20:429-32.
 
231 - Scheri RP (2007)
Scheri RP, Essner R, Turner RR, Ye X, Morton DL: Isolated tumor cells in the sentinal node affect long-term prognosis of patients with melanoma, Ann Surg Oncol 2007, 14:2861-6.
 
232 - Schmid-Wendtner MH (2000)
Schmid-Wendtner MH, Brunner B, Konz B et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000;43:477-82.
 
233 - Schraffordt Koops H (1998)
Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, World Health Organization Melanoma Programme Trial 15. J Clin Oncol 1998;16:2906-12.
 
234 - Scolyer RA (2010)
Scolyer RA, Murali R, McCarthy SW, Thompson JF: Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy, Arch Pathol Lab Med. 2010;134:1770-7.
 
235 - Shidham VB (2003)
Shidham VB, Qi D, Rao RN, Acker SM, Chang CC, Kampalath B, et al. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase, BMC Cancer 2003, 3:15.
 
236 - Shidham VB (2001)
Shidham VB, Qi DY, Acker S, Kampalath B, Chang CC, George V, et al: Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45, Am J Surg Pathol 2001, 25:1039-46.
 
237 - Shivers SC (2001)
Shivers SC, Li W, Lin J, Stall A, Stafford M, Messina J, Get al: The clinical relevance of molecular staging for melanoma, Recent Results Cancer Res 2001, 158:187-99.
 
238 - Shivers SC (1998)
Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, et al.: Molecular staging of malignant melanoma: correlation with clinical outcome, JAMA 1998, 280:1410-5.
 
239 - Shivers SC (1998)
Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410-5.
 
240 - Siesling S (2011)
Siesling S, Visser O, Luth TK, et al. Volwassen kankerpatiënten overleven langer in Nederland 5-jaarsoverleving 12% toegenomen tussen 1989-1993 en 2004-2008.Ned Tijdschr Geneeskd. 2011;155:A3169.
 
241 - Singh B et al. (2008)
Singh B et al., Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Research, 2008(of Publication: October 2008): p. 18 (5) (pp 346-352), 2008.
 
242 - Skin Neoplasms
Skin Neoplasms. PLoS ONE 4(4): e5375. doi:10.1371/journal.pone.0005375.
 
243 - Soo V (2007)
Soo V, Shen P, Pichardo R, Azzazy H, Stewart JH, Geisinger KR, Levine EA: Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology, Ann Surg Oncol 2007, 14:1612-7.
 
244 - Sladden MJ (2009)
Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, et al. JF. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009 (4):CD004835
 
245 - de Snoo FA (2008)
de Snoo FA, Bishop T, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation positive melanoma families. Clin Cancer Res. 2008; 14: 7151-7.
 
246 - Soong S (2010)
Soong S, Ding S, Coit D, Balch CM, Gerschenwald JE, Thompson JF et al. Predicting Survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 2010;2010 Aug;17(8):2006-14.
 
247 - Jeffrey A. Sosman (2012)
Sosman, M.D., Kevin B. Kim, M.D., Lynn Schuchter, M.D., Rene Gonzalez, M.D., Anna C. Pavlick, et al. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib.N Engl J Med 2012; 366:707-714, February 23, 2012.
 
248 - Starz H (2004)
Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Annals of surgical oncology: the official journal of the Society of Surgical Oncology 2004;11 (3 Suppl):162S-8S.
 
249 - Starz H (2001)
Starz H, Balda BR, Kramer KU, Buchels H, Wang H: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma, Cancer 2001, 91:2110-21.
 
250 - Stojadinovic A (2002)
Stojadinovic A, Allen PJ, Clary BM, Busam KJ, Coit DG: Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma, Ann Surg 2002, 235:92-8.
 
251 - Strobbe LJA (1998)
Strobbe LJA, Hart AAM, Rümke Ph, Israels SP, Nieweg OE, Kroon BBR. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Research 1998;7:507-12.
 
252 - Strojan P (2010)
Strojan P, Jancar B, Cemazar M, Perme MP, Hocevar M. Melanoma metastases to the neck nodes: role of adjuvant irradiation. Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1039-45.
 
253 - Sumner WE 3rd (2002)
Sumner WE 3rd, Ross MI, Mansfield PF, et al. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer 2002;95:354-60.
 
254 - Swetter S (2002)
Swetter S, Carroll LA., Johnson DL et al. Positron Emission Tomography is luperior to Computd Tomography for metastatic detection in melanoma patientsl. Annals of Surgical Oncology. 2002;9 (7): 646-53.
 
255 - Tanis PJ (2002)
Tanis PJ, Hart AAM, Nieweg OE, Kroon BBR. The illusion of a learning phase for lymphatic mapping.Ann Surg Oncol 2002;9:142-7.
 
256 - Thomas JM (2006)
Thomas JM. Sydney Melanoma Unit patients in breach of multicentre selective lymphadenectomy trial protocol? (2). ANZ Journal of Surgery 2006;76 (11):1038-9.
 
257 - Thomas JM (2002)
Thomas JM, Newton-Bishop JA. Surgical margin excision width in high risk (minimum depth 2 mm) cutaneous malignant melanoma: A randomized trial of 1 cm versus 3 cm excision margins in 900 patients. Proc Am Assoc Clin Oncol 2002;1358:34a.
 
258 - Thomas JM (2009)
Thomas JM. Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS 2009;62(4):442-6.
 
259 - Thompson JF (2000)
Thompson JF, Uren RF. What is a ‘sentinel’ lymph node?Eur J Surg Oncol 2000;26:103-4.
 
260 - Travers RL (1995)
Travers RL, Sober SJ, Berwick M, et al. Increased thickness of pregnancy-associated melanoma. Br J Dermatol 1995;132:876-83.
 
261 - Uren RF (2000)
Uren RF, Thompson JF, Howman-Giles R. Sentinel nodes. Interval nodes, lymphatic lakes, and accurate sentinel node identification. Clin Nucl Med 2000;25:234-6.
 
262 - US (2001)
US, Preventive Services Taskforce. Screening for skin cancer: recommendations and rationale. Am J Prev Med 2001;20:44-6.
 
263 - Vasen HF (1989)
Vasen HF, Bergman W, van Haeringen A, Scheffer E, van Slooten EA. The familial dysplastic nevus syndrome. Natural history and the impact of screening on prognosis. A study of nine families in the Netherlands. Eur. J. Cancer Clin. Oncol. 1989; 25: 337-41.
 
264 - Vasen HF (2000)
Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer. 2000; 87(6):809-11.
 
265 - Vasen HF (2011)
Vasen HF, et al., Magnetic Resonance Imaging Surveillance Detects Early-Stage Pancreatic Cancer in Carriers of a p16-Leiden Mutation. Gastroenterology. 2011;140(3):850-6.
 
266 - Veenhuizen KC (1997)
Veenhuizen KC, Wit PE de, Mooi WJ, Scheffer E, Verbeek AL, Ruiter DJ. Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party. J Pathol 1997;182:266-72.
 
267 - Veerbeek L (2010)
Veerbeek L, van de Poll-Franse LV, Bekkenk MW, et al. Betere navolging van de richtlijn ‘Melanoom’. Ned Tijdschr Geneeskd. 2010;154:A858.
 
268 - Veit-Haibach P (2009)
Veit-Haibach P, Vogt FM, Jablonka R et al. Diagnostic accuracy op contraxt-enhanced FDG-ET/CT in primary staging of cutaneous malignant melanoma." Eur J Nucl Med Mol. 2009; Imaging 36: 1910-8.
 
269 - Veronesi U (1982)
Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913-6.
 
270 - Veronesi U (1991)
Veronesi U, Cascinelli N. Narrow excision (1 cm margin) – a safe procedure for thin cuteanous melanoma. Arch Surg 1991;126:438-41.
 
271 - Viros A (2008)
Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, et al. Improving Melanoma Classification by Integrating Genetic and Morphologic Features. PLoS Med. 2008 Jun 3;5(6):e120.
 
272 - Voit C et al (2010)
Voit C et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. Journal of clinical oncology. J Clin Oncol. 2010 Feb 10;28(5):847-52. Epub 2010 Jan 11.
 
273 - Vries E de (2003)
Vries E de, Schouten LJ, Visser O, Eggermont AAM, Coebergh JW and the working group of Regional Cancer Registries. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a northwest to southeast gradient? Eur J Cancer 2003;39:1439-46.
 
274 - Vries E de (2003)
Vries E de, Bray F, Coebergh JWW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality, but recent stabilizations in western Europe and decreases in Scandinavia.Int J Cancer 2003;107:119-26.
 
275 - Vries E de (2005)
Vries E de, Poll-Franse LV van de, Louwman WJ, Gruijl FR de, Coebergh JW.Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol. 2005 Mar;152(3):481-8.
 
276 - Vries E de (2007)
Vries E de, Houterman S, Janssen-Heijnen ML, Nijsten T, van de Schans SA, Eggermont AM, Coebergh JW.Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol. 2007 Jun;18(6):1110-6. Epub 2007 Apr 13.
 
277 - Vuylsteke RJCLM (2003)
Vuylsteke RJCLM, Leeuwen PAM van, Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003;21:1057-65.
 
278 - Wagner JD (2000)
Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000;89:453-62.
 
279 - Walling HW (2007)
Walling HW, Scupham RK et al. Staged excision versus Mohs micorgraphic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 2007;57:659-64.
 
280 - Weinstoch MA (1987)
Weinstoch MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. 1987 Br. J. Dermatol 116(3): 303-310.
 
281 - Wheatley K (2003)
Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003; 29: 241–52.
 
282 - Whiteman D (1994)
Whiteman D, Green A. Melanoma and Sunburn. Cancer Causes Control. 1994 Nov;5(6):564-72.
 
283 - Whiteman DC (2010)
Whiteman DC. Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges. Expert Rev Anticancer Ther 2010; 10: 615-8.
 
284 - De Wilt JHW (2008)
De Wilt JHW, van AkkooiACJ, Verhoef C, Eggermont AMM. Detection of melanoma micrometastases in sentinel nodes; the cons. Surg Oncol 2008; 17:175-81.
 
285 - Wolff T (2009)
Wolff T, Tai E and Miller T. Screening for skin cancer: an update of the evidence for the US Preventive Services Taskforce. Ann Int Med 2009;150:194-8.
 
286 - Wood TF (2001)
Wood TF, DiFronzo LA, Rose DM, Haigh PI, Stern SL, Wanek L, et al. Does complete resection of melanoma metastatic to solid intra- abdominal organs improve survival? Ann Surg Oncol 2001;8:658-62.
 
287 - Xing Y et al (2011)
Xing Y et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natnl Canc Inst 2011;103(2):129-42.
 
288 - Yu LL (1999)
Yu LL, Flotte TJ, Tanabe KK, Gadd MA, Cosimi AB, Sober AJ, Mihm MC, Jr., Duncan LM: Detection of microscopic melanoma metastases in sentinel lymph nodes, Cancer 1999, 86:617-27.
 
289 - Zalaudek I (2004)
Zalaudek I, Argenziano G, Ferrara G, Soyer HP, Corona R, et al. Clinically equivocal melanocytic skin lesions withy features of regression: a dermoscopic-pathological study. Br J Dermatol. 2004;150: 64–71.
 
290 - Baughan CA (1993)
Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol). 1993;5(3):174-80.
 
291 - Bernengo (2005)
Bernengo, M. G., P. Quaglino, et al. (2005). Time course and pattern of first relapse in stage I-II primary cutaneous melanoma: A multivariate analysis of disease-free survival in 3174 patients followed-up at the Turin Melanoma Centre from 1975 to 2004. G Ital Dermatol Venereol 140(3): 191-200.
 
292 - Bradford (2010)
Bradford, P. T., D. M. Freedman, et al. (2010). "Increased risk of second primary cancers after a diagnosis of melanoma." Arch Dermatol 146(3): 265-272.
 
293 - DiFronzo LA (2001)
DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer 2001;91:1520-4. 
 
294 - Francken AB (2007)
Francken AB, Shaw HM, Accortt NA, Soong S-J, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14(6):1924-33.
 
295 - Francken (2008)
Francken, A. B., N. A. Accortt, et al. (2008). "Follow-up schedules after treatment for malignant melanoma." Br J Surg 95(11): 1401-1407.
 
296 - Garbe C (2003)
Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21(3):520-9.
 
297 - Gezondheidsraad (2007)
Gezondheidsraad. Nacontrole in de oncologie. Doelen onderscheiden, inhoud onderbouwen. Den Haag: Gezondheidsraad, 2007; publicatienr. 2007/10.
 
298 - Hansel (2010)
Hansel, G., J. Schonlebe, et al. (2010). "Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more." J Eur Acad Dermatol Venereol 24(7): 833-836.
 
299 - Hoffman B (2006)
Hoffman B, Stovall E. Survivorship perspective and advocacy. J Clin Oncol. 2006; 24(32): 5154-9.
 
300 - Hofmann U (2002)
Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002;87:151-7.
 
301 - Hofmann U (2002)
Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87(2):151-7.
 
302 - Hohnheiser (2011)
Hohnheiser, A. M., O. Gefeller, et al. (2011). "Malignant melanoma of the skin: long-term follow-up and time to first recurrence." World J Surg 35(3): 580-589.
 
303 - Jansen L (2000)
Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Valdés Olmos RA, Kroon BBR. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000;87:484-9.
 
304 - Jillella A (1995)
Jillella A, Mani S, Nair B, Poo WJ, Bolognia J, Ariyan S, et al. The role for close follow-up of melanoma patients with AJCC stages I-III: a preliminary analysis. Proc ASCO 1995;14:413.
 
305 - Kahle B (2003)
Kahle B, Hoffend J, Wacker J, Hartschuh W. Preoperative ultrasonographic identification of the sentinel lymph node in patients with malignant melanoma. Cancer. 2003 Apr 15;97(8):1947-54.
 
306 - Khlat M (1992)
Khlat M, Vail A, Parkin DM, Green A. Mortality from melanoma in migrants to Australia: variation by age at arrival and duration of stay. Am J Epidemiol 1992 ;135:1103-13.
 
307 - Kittler H (2001)
Kittler H, Weitzdorfer R, Pehamberger H, Wolff K, Binder M. Compliance with follow-up and prognosis among patients with thin melanomas. Eur J Cancer 2001;37:1504-9. 
 
308 - Leiter U (2010)
Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res. 2010;20(3):240-6.
 
309 - Leiter (2011)
Leiter, U., P. G. Buettner, et al. (2011). "Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry."J Am Acad Dermatol. 2012 Jan;66(1):37-45. Epub 2011 Jun 23.
 
310 - Leman (2003)
Leman, J. A. and R. M. Mac Kie (2003). "Late (> 10 years) recurrence of melanoma: the Scottish experience." Br J Dermatol 148(2): 372-373.
 
311 - Lock-Andersen J (1999)
Lock-Andersen J, Drzewiecki KT, Wulf HC. Eye and hair colour, skin type and constitutive skin pigmentation as risk factors for basal cell carcinoma and cutaneous melanoma. A Danish case control study. Acta Derm Venereol 1999;79:74-80.
 
312 - McCaul (2008)
McCaul, K. A., L. Fritschi, et al. (2008). "The incidence of second primary invasive melanoma in Queensland, 1982-2003." Cancer Causes Control 19(5): 451-458.
 
313 - Meyers MO (2009)
Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009;16(4):941-7.
 
314 - Moore Dalal K (2008)
Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol. 2008;15(8):2206-14.
 
315 - Parker PA (2007)
Parker PA, Youssef A, Walker S, Basen-Engquist K, Cohen L, Gritz ER, Wei QX, Robb GL. Short-term and long-term psychosocial adjustment and quality of life in women undergoing different surgical procedures for breast cancer. Ann Surg Oncol. 2007;14(11): 3078-89.
 
316 - Poo-Hwu WJ (1999)
Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999;86:2252-8.
 
317 - Romano E (2010)
Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042-7.
 
318 - Ruark DS (1993)
Ruark DS, Shaw HM, Ingvar C, McCarthy WH, Thompson JF. Who detects the first recurrence in stage I cutaneous malignant melanoma: patient or doctor? Melanoma Research 1993(suppl 1):44.
 
319 - Stanton AL (2006)
Stanton AL. Psychosocial concerns and interventions for cancer survivors. J Clin Oncol. 2006; 24(32): 5132-7.
 
320 - Vestergaard ME (2008)
Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008 Sep;159(3):669-76. Epub 2008 Jul 4.
 
321 - Amanuel B (2012)
Amanuel B, Grieu F, Kular J, et al. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology. 2012;44:357-9.
 
322 - Ascierto PA (2012)
Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. Journal of translational medicine. 2012;10:85.
 
323 - Aukema TS (2010)
Aukema TS, Valdés Olmos RA, et al. Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol. 2010: 2773-8.
 
324 - Aukema TS (2010)
Aukema TS, Valdes Olmos RA, Korse CM, et al. Kroon BB, Wouters MW, Vogel WV, et al. Utility of FDG PET-CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol. 2010;17:1657-61.
 
325 - Balch CM (1999)
Balch CM, Ross MI. Sentinel lymphadenectomy for melanoma – is it a substitute for elective lymphadenectomy? Ann Surg Oncol. 1999;6:416-7.
 
326 - Bastiaannet E (2009)
Bastiaannet E, Wobbes, T., Hoekstra, O.S., et al. Prospective Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in patients with palpable lymph node metastases: Diangnostic accuracy and impact on treatment. JCO. 2009:27: 4774-80.
 
327 - Bastian BC (2014)
Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239-71.
 
328 - Bouwhuis MG (2011)
Bouwhuis MG, Suciu S, Kruit W, et al. European Organisation for Research and Treatment of Cancer Melanoma Group. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer. 2011;47:361-8.
 
329 - Brady MS (2006)
Brady MS, Akhurst T, Spankneber K, et al.Utility of preoperative [18F]Fluorodeoxyglucose Positron Emission Tomography scanning in high-riks melanoma patients. Ann Surg Oncol. 2006;13: 525-532.
 
330 - Bronstein Y (2012)
Bronstein Y, Ng CS, Rohren E, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012;198:902-8.
 
331 - Calista D (2013)
Calista D, Vitali P, Arcangeli F. Sentinel lymph node biopsy or nodal observation in melanoma: study of an Italian series. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. G Ital Dermatol Venereol. 2013; 148: 299-305.
 
332 - Cameron DA (2001)
Cameron DA, Cornbleet MC, MacKie RM, et al. Adjuvant interferon alpha in high-risk melanoma: The Scottish study. Br J Cancer. 2001;84:1146-9.
 
333 - Chapman PB (2011)
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
 
334 - Clary BM (2001)
Clary BM, Brady MS, Lewis JJ, et al. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg. 2001;233:250-8.
 
335 - Cochrane DB (2000)
Cochrane DB. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2000;CD001215.
 
336 - Colombino M (2012)
Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522-9.
 
337 - Colombino M (2013)
Colombino M, Lissia A, Capone M, et al. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. Journal of translational medicine. J Transl Med. 2013;11:202.
 
338 - Cordova A et al. (2006)
Cordova A et al. 18 Fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) imaging versus sentinel lymph node biopsy (SLNB) in the staging of cutaneous melanoma in AJCC stage I and II. Chirurgia 2006 (of Publication: Jun 2006): p.19(189-191).
 
339 - da Rocha Dias S (2013)
da Rocha Dias S, Salmonson T, van Zwieten-Boot B, et al. The European Medicines Agency review of vemurafenib (Zelboraf(R)) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2013;49:1654-61.
 
340 - Dellestable P (2011)
Dellestable P, Granel-Brocard F, Rat AC, et al. [Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (PET/CT) and CT]. Ann Dermatol Venereol. 2011;138:377-83.
 
341 - Egberts F (2009)
Egberts F, Hitschler WN, Weichenthal M, et al. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res. 2009;19:31-5.
 
342 - Eggermont AMM (2015)
Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30
 
343 - Essner R (1999)
Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol. 1999;6:442-9.
 
344 - Estourgie SH (2003)
Estourgie SH, Nieweg OE, Valdés Olmos RA, et al. A review and evaluation of sentinelnodebiopsies in 250 patients with cutaneous melanoma with a median follow up of six years. Ann Surg Oncol. 2003;10:681-8.
 
345 - Etchebehere EC (2010)
Etchebehere EC, Romanato JS, Santos AO, et al. Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun. 2010;31:925-30.
 
346 - Finkelstein SE (2004)
Finkelstein SE, Carrasquillo JA, Hoffman JM et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11:731-8.
 
347 - Flaherty L (2014)
Flaherty L, Hamid O, Linette G, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer Journal. 2014;20:18-24.
 
348 - Fogarty GB (2006)
Fogarty GB, Tartaglia C. The Utility of Magnetic Resonance Imaging in the Detection of Brain Metastases in the Staging of Cutaneous Melanoma. Clinical Onc. 2006;18:360-2.
 
349 - Gonzalez D (2013)
Gonzalez D, Fearfield L, Nathan P, et al. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol. 2013;168:700-7
 
350 - Greaves WO (2013)
Greaves WO, Verma S, Patel KP, et al. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. J Mol Diagn. 2013;15:220-6.
 
351 - Gutzmer R (2005)
Gutzmer R, Al Ghazal M, Geerlings H, et al. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Brit J Derm. 2005;153:1137-41.
 
352 - Halait H (2012)
Halait H, Demartin K, Shah S, et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol. 2012;21:1-8.
 
353 - Harlow SP (2001)
Harlow SP, Krag DN, Ashikaga T, et al. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res. 2001;11:45-55.
 
354 - Heidorn SJ (2010)
Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140:209-21.
 
355 - Hocevar M (2004)
Hocevar M, Bracho M, Pogacnik A, et al. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res. 2004;14:533-6.
 
356 - Iagaru A (2007)
Iagaru A, Quon A, Johnson D, et al. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2007;9:50-7.
 
357 - Jouvet JC (2014)
Jouvet JC, Thomas L, Thomson V, et al. Whole-body MRI with diffusion-weighted sequences compared with 18FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol. 2014;28:176-85.
 
358 - Kahle B (2003)
Kahle B, Hoffend J, Wacker J, et al. Preoperative ultrasonographic identification of the sentinel lymph node in patients with malignant melanoma. Cancer. 2003;97:1947-54.
 
359 - Kapteijn BAE (1996)
Kapteijn BAE, Nieweg OE, Valdés Olmos RA, et al. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with cutaneous melanoma. J Nucl Med. 1996;37:972-5.
 
360 - Kell MR (2007)
Kell MR, Ridge JA, Joseph N, et al. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Oncol. 2007;33:911-3.
 
361 - Klein O (2013)
Klein O, Clements A, Menzies AM, et al. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer. 2013;49:1073-9
 
362 - Klode J (2010)
Klode J, Dissemond J, Grabne S, et al. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: A retrospective analysis of 61 patients with malignant melanoma in American joint committee on cancer stages I and II. Dermatologic Surg. 2010;36:439-45.
 
363 - Koskivuo I (2007)
Koskivuo I, Talve L, Vihinen P, et al. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol. 2007;14:3566-74
 
364 - Krug B (2008)
Krug B, Crott R, Lonneux M, et al. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology. 2008:249:836-844.
 
365 - Krug B (2010)
Krug B, Pirson AS, Crott R, et al. The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging. 2010;37:1434-5.
 
366 - Kudchadkar RR (2013)
Kudchadkar RR, Smalley KS, Glass LF, et al. Targeted therapy in melanoma. Clin Dermatol. 2013;31:200-8.
 
367 - Kwong LN (2014)
Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene. 2014 2;33:1-9
 
368 - Laurent V (2010)
Laurent V, Trausch G, Bruot O, et al. Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol. 2010;75:376-83.
 
369 - Leiter U (2010)
Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17:129-37.
 
370 - Long GV (2013)
Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61-5.
 
371 - Lovly CM (2012)
Lovly CM, Dahlman KB, Fohn LE, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 2012;7:e35309.
 
372 - Luke JJ (2012)
Luke JJ, Hodi FS. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012;18:9-14.
 
373 - McArthur GA (2014)
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323-32.
 
374 - McClain SE (2012)
McClain SE, Shada AL, Barry M, et al. Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. Melanoma res. 2012; 22: 302-9.
 
375 - Menzies AM (2012)
Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy. 2012;6:391-405.
 
376 - Morton DL (1999)
Morton DL, Bostick PJ. Will the true sentinel node please stand? Ann Surg Oncol. 1999;6:12-4.
 
377 - Morton DL (2005)
Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Annals of Surgery. 2005; 242: 302-11; discussion 11-3.
 
378 - Morton DL (2014)
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Eng. J. Med. 2014; 370: 599-609.
 
379 - Morton DL (2006)
Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17. Erratum in: N Eng J Med. 2006;355:1944
 
380 - Morton DL (2014)
Morton DL, Thompson JF, Cochran AJ, et al.; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.
 
381 - Morton DL (1992)
Morton DL, Wen D, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-9.
 
382 - Nieweg OE (1998)
Nieweg OE, Jansen L, Kroon BBR. Technique of lymphatic mapping and sentinel node biopsy for melanoma. Eur J Surg Oncol. 1998;24:520-4.
 
383 - Nieweg OE (2001)
Nieweg OE, Jansen L, Tanis PJ, et al. Verbeterde prognose van melanoma cutis door schildwacht- klierprocedure is nog niet aangetoond. Ned Tijdschr Dermatol Venereol. 2001;11:246-8.
 
384 - Peric B (2011)
Peric B, Zagar I, Novakovic S, et al. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer. 2011;11:328.
 
385 - Pfannenberg C (2007)
Pfannenberg C, Aschoff P, Schanz S, et al. Prospective comparison of [18F]Fluorode-oxyglucose Positron Emission Tomography. Computed Tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43: 557-64.
 
386 - Pfluger T (2011)
Pfluger T, Melzer HI, Schneider V, et al. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging. 2011;38:822-31.
 
387 - Pijpers R (1997)
Pijpers R, Borgstein PJ, Meijer S, et al. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg. 1997;21:788-92; discussion 793
 
388 - Reinhardt MJ (2006)
Reinhardt MJ, Joe AY, Jaeger U et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consectutive patients. J Clin Onol. 2006;24:1178-86.
 
389 - Reintgen D (1994)
Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759-67.
 
390 - Römer W (2006)
Römer W, Nörmayr A, Fiedler E, et al. Retrospective interactive rigid fusion of 18F-FDG PET and CT. Nuklearmedzin. 2006;45:88-95.
 
391 - Roozendaal GK (2001)
Roozendaal GK, Vries JDH de, Poll D van, et al. Sentinel nodes outside lymph node basins in melanoma patients. Br J Surg. 2001;88:305-8.
 
392 - Rubinstein JC (2010)
Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. Journal Transl Med. 2010;8:67.
 
393 - Saint-Jean M (2014)
Saint-Jean M, Quereux G, Nguyen JM, et al. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol. 2014;134:1468-70.
 
394 - Sanki A (2009)
Sanki A, Uren RF, Moncrieff M, et al., Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol. 2009;27:5614-9.
 
395 - Satzger I (2011)
Satzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol. 2011; 18: 514-20.
 
396 - Sosman JA (2012)
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-14.
 
397 - Speijers MJ (2015)
Speijers MJ, Bastiaannet E, Sloot S, et al. Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? : A Single-Institution Database Study on the Prognostic Value of Tumor Mitotic Rate for Sentinel Lymph Node Status and Survival of Cutaneous Melanoma Patients. Ann Surg Oncol. 2015;22:2978-87
 
398 - Starz H (2007)
Starz H, Balda BR. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients. Int J Cancer. 2007;121:689-93.
 
399 - Starz H (2004)
Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol. 2004;11:162S-8S.
 
400 - Stones CJ (2013)
Stones CJ, Kim JE, Joseph WR, et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Frontiers in Genetics. 2013;4:66.
 
401 - Strobel K (2007)
Strobel K, Skalsky J, Kalff V, et al. Tumour assessment in advanced melanoma: value of FDG-PET-CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging 2007;34:1366-75.
 
402 - Subesinghe M (2013)
Subesinghe M, Marples M, Searsbrook AF, et al. Clinical impact of 18F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. Insight Imaging. 2013;4:701-709.
 
403 - Sumner WE 3rd (2002)
Sumner WE 3rd, Ross MI, Mansfield PF, et al. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002;95:354-60.
 
404 - Swetter S (2002)
Swetter S, Carroll LA., Johnson DL, et al. Positron Emission Tomography is luperior to Computd Tomography for metastatic detection in melanoma patientsl. Ann Surg Oncol. 2002;9:646-53.
 
405 - Tanis PJ (2002)
Tanis PJ, Hart AAM, Nieweg OE, et al. The illusion of a learning phase for lymphatic mapping. Ann Surg Oncol. 2002;9:142-7.
 
406 - Thompson JF (2000)
Thompson JF, Uren RF. What is a ‘sentinel’ lymph node? Eur J Surg Oncol. 2000;26:103-4.
 
407 - Uren RF (2000)
Uren RF, Thompson JF, Howman-Giles R. Sentinel nodes. Interval nodes, lymphatic lakes, and accurate sentinel node identification. Clin Nucl Med. 2000;25:234-6.
 
408 - Van Akkooi ACJ (2006)
Van Akkooi ACJ, De Wilt HW, Verhoef C, et al. Clinical Relevance of Melanoma Micrometastases (<0.1mm) in Sentinel Nodes: are these nodes to be considered negative? Ann Oncol. 2006;17:1578-85.
 
409 - Van der Ploeg AP (2014)
Van der Ploeg AP, Haydu LE, Spillane AJ, et al. Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution. Ann Surg. 2014;260:149-57.
 
410 - Van Poll D (2005)
Van Poll D, Thompson JF, Colman MH, et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12:597-608.
 
411 - Van Rijk MC (2006)
Van Rijk MC, Teertstra HJ, Peterse JL, et al. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol. 2006;11:1511-6.
 
412 - Veit-Haibach P (2009)
Veit-Haibach P, Vogt FM, Jablonka R, et al. Diagnostic accuracy of contraxt-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol. 2009;36:1910-8.
 
413 - Voit C (2010)
Voit C, van Akkooi AC, Schäfer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol. 2010;28:847-52.
 
414 - Vuylsteke RJCLM (2003)
Vuylsteke RJCLM, Leeuwen PAM van, Statius Muller MG, et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol. 2003;21:1057-65.
 
415 - Wagner JD (2000)
Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000;89:453-62.
 
416 - Whiteman DC (2011)
Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011;24:879-97.
 
417 - Wieder HA (2013)
Wieder HA, Tekin G, Rosenbaum-Krumme S, et al. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. Nuklearmedizin. 2013;52:198-203.
 
418 - Xing Y (2011)
Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129-42.
 
420 - Yancovitz M (2012)
Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One. 2012;7:e29336.
 
421 - Yang H (2010)
Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010;70:5518-27.